Screener
Ligand Pharmaceuticals LGND Primrose mRNA — Financial Royalty Assets, Allowance
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsAllowance.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 / Gross carrying value(1) | June 30, 2026 / Allowance | June 30, 2026 / Net carrying value (1) | December 31, 2025 / Gross carrying value(1) | December 31, 2025 / Allowance | December 31, 2025 / Net carrying value(1) |
|---|---|---|---|---|---|---|
| Tolerance Therapeutics (Tzield®) | 25,470 | (99) | 25,371 | 25,257 | (98) | 25,159 |
| Ohtuvayre inventors | 19,957 | (179) | 19,778 | 16,921 | (151) | 16,770 |
| Elutia (CorMatrix) | 6,062 | (837) | 5,225 | 6,607 | (1,107) | 5,500 |
| AT220 | 4,442 | (109) | 4,333 | 5,132 | (132) | 5,000 |
| Primrose mRNA | 3,281 | (98) | 3,183 | 3,281 | (98) | 3,183 |
| Zerion | 2,640 | (79) | 2,561 | — | — | — |
| Others | 5,729 | (212) | 5,517 | 5,769 | (214) | 5,555 |
| Total financial royalty assets, net | $209,699 | $(2,489) | $207,210 | $222,375 | $(2,706) | $219,669 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's primrose mrna — financial royalty assets, allowance?
- Ligand Pharmaceuticals (LGND) reported primrose mrna — financial royalty assets, allowance of $98K in Q2 2026.
- What does primrose mrna — financial royalty assets, allowance mean?
- Reflects the cumulative valuation adjustment or reserve established against the gross carrying value of royalty assets in the mRNA segment. This allowance accounts for expected credit losses or potential uncollectibility of future royalty streams. It is a critical indicator of management's assessment of the credit risk and recoverability of the segment's royalty-based assets.
Ask your AI about Ligand Pharmaceuticals's primrose mrna — financial royalty assets, allowance.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude